We developed PASSPORT-seq (parallel assessment of polymorphisms in miRNA target-sites by sequencing), a high-throughput bioassay that involves pooled synthesis, parallel cloning and single-well transfection followed by next-generation sequencing (NGS) to functionally test 100s of mirSNPs at once. This assay produced results that are reproducible and consistent with luciferase reporter assays, a gold-standard platform widely used to assess gene expression in vitro. We also demonstrate the application of this assay to test 111 genetic variants that are predicted to alter miRNA regulation of 17 pharmacogenes.
